Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
Epistemonikos ID: dc833276265272ea2c32d666a102248caefbddf1
First added on: Mar 31, 2022